Prelude Therapeutics

PRLD · NASDAQ

$3.53+$0.14 (+4.13%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $3.39

PRLD analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy4
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $8.67 (+145.6% upside)

Low: $6.06
Now: $3.53
High: $10.50

Upgrades and downgrades

The latest rating actions, newest first

PRLD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Sep 17, 2026	Initiates	Overweight	$12.00	50%
HC Wainwright & Co.	Jul 29, 2026	Maintains	Buy	$8.00	41%
Goldman Sachs	May 15, 2026	Initiates	Early-Stage Biotech	—	53%
D. Boral Capital	May 4, 2026	Initiates	Buy	$9.00	29%
HC Wainwright & Co.	Apr 27, 2026	Maintains	Buy	$5.00 → $8.00	41%
Citizens	Mar 11, 2026	Maintains	Market Outperform	$3.00 → $6.00	35%

The case for and against

Updated Oct 21, 2026

Bull case

Prelude Therapeutics is viewed favorably because it combines a differentiated precision-oncology pipeline with external validation and improving financial flexibility. Its mutant-selective JAK2V617F program received a November 2025 Incyte agreement with $60 million upfront, including a $25 million equity investment, plus potential for over $800 million in future payments, while the KAT6A degrader showed complete tumor regressions in AACR 2026 preclinical data and supports a large HR+/HER2- breast cancer opportunity. The company ended 2025 with $106.4 million in cash and equivalents, raised approximately $100 million in April 2026, and guided runway into Q2 2027, giving it funding to advance IND milestones and broaden its degrader platform, including DACs with AbCellera.

Bear case

Prelude Therapeutics is fundamentally challenged by its lack of revenue and the need for continued external funding, making it dependent on clinical progress and exposing shareholders to dilution risk before it becomes self-sustaining. Its investment case also carries elevated clinical, regulatory, partnership, commercial, and IP risk, with no guarantee it can secure attractive deal terms or successfully defend its patent estate around oral degraders and formulation claims. In a highly competitive oncology landscape, any delays or setbacks in advancing its selective KAT6A degraders, mutant-selective JAK2V617F JH2 inhibitors, or DAC programs could impair execution and undermine long-term value creation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.